Visit us at the #AACR25 in #Chicago, where we present #CancerResearch in Germany. 👩🏽🔬👨🏽🔬 🇩🇪
📍Exhibition at booth #842 from April 27 to 30
@nct-heidelberg.bsky.social @DKTK @theaacr.bsky.social
📍Exhibition at booth #842 from April 27 to 30
@nct-heidelberg.bsky.social @DKTK @theaacr.bsky.social
April 28, 2025 at 11:44 AM
Visit us at the #AACR25 in #Chicago, where we present #CancerResearch in Germany. 👩🏽🔬👨🏽🔬 🇩🇪
📍Exhibition at booth #842 from April 27 to 30
@nct-heidelberg.bsky.social @DKTK @theaacr.bsky.social
📍Exhibition at booth #842 from April 27 to 30
@nct-heidelberg.bsky.social @DKTK @theaacr.bsky.social
The first publication by my independent research group in collaboration with many partners in Frankfurt. @loewe-fci.bsky.social @goetheuni.bsky.social #EdingerInstitut #DKTK @schuckjonas.bsky.social @zezzenya.bsky.social
October 22, 2025 at 7:36 AM
The first publication by my independent research group in collaboration with many partners in Frankfurt. @loewe-fci.bsky.social @goetheuni.bsky.social #EdingerInstitut #DKTK @schuckjonas.bsky.social @zezzenya.bsky.social
@nct-heidelberg.bsky.social @dkfz.bsky.social DKTK HARPOON Symposium brought together leading experts from clinical & research settings to discuss cutting-edge advances in precision oncology, including key contributions from #CCE members @vhio.bsky.social @crukcamcentre.bsky.social @gustaveroussy.fr
December 2, 2025 at 10:19 AM
@nct-heidelberg.bsky.social @dkfz.bsky.social DKTK HARPOON Symposium brought together leading experts from clinical & research settings to discuss cutting-edge advances in precision oncology, including key contributions from #CCE members @vhio.bsky.social @crukcamcentre.bsky.social @gustaveroussy.fr
Inmaculada Martínez Reyes vom Deutschen Konsortium für Translationale Krebsforschung (DKTK), Standort Charité Berlin, wird mit dem SWISS BRIDGE Award ausgezeichnet. Die Immunologin erhält den Preis für die Entwicklung innovativer zellulärer Immuntherapien. 👏
t1p.de/tbtlq
t1p.de/tbtlq
DKTK-Wissenschaftlerin mit dem SWISS BRIDGE Award ausgezeichnet
Inmaculada Martínez Reyes vom Deutschen Konsortium für Translationale Krebsforschung (DKTK), Standort Charité Berlin, wird mit dem SWISS BRIDGE Award ausgezeichnet. Die Immunologin erhält den Preis fü...
t1p.de
October 31, 2025 at 12:25 PM
Inmaculada Martínez Reyes vom Deutschen Konsortium für Translationale Krebsforschung (DKTK), Standort Charité Berlin, wird mit dem SWISS BRIDGE Award ausgezeichnet. Die Immunologin erhält den Preis für die Entwicklung innovativer zellulärer Immuntherapien. 👏
t1p.de/tbtlq
t1p.de/tbtlq
Dear Katharina Imkeller @imkeller.bsky.social, from LOEWE Center FCI @loewe-fci.bsky.social, @goetheuni.bsky.social, congratulations👏🏼to you, your research group, + partners on this👍🏼important🗞️publication!⤵️ #EdingerInstitut #DKTK @schuckjonas.bsky.social @zezzenya.bsky.social
The first publication by my independent research group in collaboration with many partners in Frankfurt. @loewe-fci.bsky.social @goetheuni.bsky.social #EdingerInstitut #DKTK @schuckjonas.bsky.social @zezzenya.bsky.social
October 22, 2025 at 8:53 AM
Dear Katharina Imkeller @imkeller.bsky.social, from LOEWE Center FCI @loewe-fci.bsky.social, @goetheuni.bsky.social, congratulations👏🏼to you, your research group, + partners on this👍🏼important🗞️publication!⤵️ #EdingerInstitut #DKTK @schuckjonas.bsky.social @zezzenya.bsky.social
Mit Beginn der neuen Förderperiode 2026 bis 2030 hat das DKTK einen neuen Sprecher: Stefan Pfister. Er übernimmt das Amt von Michael Baumann, Vorstandsvorsitzender des DKFZ, der das DKTK in den vergangenen zehn Jahren maßgeblich geprägt hat.
t1p.de/rhho5
t1p.de/rhho5
Stefan Pfister neuer Sprecher des DKTK
Mit Beginn der neuen Förderperiode 2026 bis 2030 hat das Deutsche Konsortium für Translationale Krebsforschung (DKTK) einen neuen Sprecher: Stefan Pfister, Direktor am Hopp-Kindertumorzentrum Heidelbe...
t1p.de
June 2, 2026 at 12:43 PM
Mit Beginn der neuen Förderperiode 2026 bis 2030 hat das DKTK einen neuen Sprecher: Stefan Pfister. Er übernimmt das Amt von Michael Baumann, Vorstandsvorsitzender des DKFZ, der das DKTK in den vergangenen zehn Jahren maßgeblich geprägt hat.
t1p.de/rhho5
t1p.de/rhho5
🌊 HARPOON Conference 2025 — PREDICT Study 🎯
Happy to play a small part in this high-quality DKFZ/DKTK/NCT meeting and to share our latest results from the PREDICT study, which I’m proud to co-lead with Prof. Jessica Hassel.
#HARPOON #DKFZ #DKTK #NCT #immunotherapy #cancercoreeurope #melanoma
Happy to play a small part in this high-quality DKFZ/DKTK/NCT meeting and to share our latest results from the PREDICT study, which I’m proud to co-lead with Prof. Jessica Hassel.
#HARPOON #DKFZ #DKTK #NCT #immunotherapy #cancercoreeurope #melanoma
November 27, 2025 at 5:52 PM
🌊 HARPOON Conference 2025 — PREDICT Study 🎯
Happy to play a small part in this high-quality DKFZ/DKTK/NCT meeting and to share our latest results from the PREDICT study, which I’m proud to co-lead with Prof. Jessica Hassel.
#HARPOON #DKFZ #DKTK #NCT #immunotherapy #cancercoreeurope #melanoma
Happy to play a small part in this high-quality DKFZ/DKTK/NCT meeting and to share our latest results from the PREDICT study, which I’m proud to co-lead with Prof. Jessica Hassel.
#HARPOON #DKFZ #DKTK #NCT #immunotherapy #cancercoreeurope #melanoma
In Limbo w/ DKTK, King Sized Coffin, Dirty-930
Art House Theater & Gallery
Minneapolis
7:00 PM
Art House Theater & Gallery
Minneapolis
7:00 PM
September 25, 2026 at 8:23 AM
In Limbo w/ DKTK, King Sized Coffin, Dirty-930
Art House Theater & Gallery
Minneapolis
7:00 PM
Art House Theater & Gallery
Minneapolis
7:00 PM
Today is my last day at the @uoe-igc.bsky.social in Edinburgh, as I'm starting my own lab in Munich as part of the German Cancer Consortium (DKTK), DKFZ and the LMU. I'll continue to focus on DNA damage and mutagenesis to determine their role in somatic evolution and disease.
July 18, 2025 at 8:44 AM
Today is my last day at the @uoe-igc.bsky.social in Edinburgh, as I'm starting my own lab in Munich as part of the German Cancer Consortium (DKTK), DKFZ and the LMU. I'll continue to focus on DNA damage and mutagenesis to determine their role in somatic evolution and disease.
PAMSARC: Newly opened, academic phase 2 trial, enabled by DKFZ NCT/DKTK MASTER and HEROES-AYA, evaluating pasireotide as maintenance therapy in patients with synovial sarcoma and desmoplastic small round cell tumor and aberrant expression of somatostatin receptor family members (NCT06456359)
January 20, 2025 at 10:02 PM
PAMSARC: Newly opened, academic phase 2 trial, enabled by DKFZ NCT/DKTK MASTER and HEROES-AYA, evaluating pasireotide as maintenance therapy in patients with synovial sarcoma and desmoplastic small round cell tumor and aberrant expression of somatostatin receptor family members (NCT06456359)
NEWS&VIEWS | LM Nascentes Melo, F Cansiz & A Tasdogan (DKTK, DE)
#AldolaseA inhibition in cancer cells turns #glycolysis into an ATP-consuming process. Imbalanced glycolysis could overcome the intrinsic metabolic plasticity of #cancer cells.
https://bit.ly/41Al0SQ
#AldolaseA inhibition in cancer cells turns #glycolysis into an ATP-consuming process. Imbalanced glycolysis could overcome the intrinsic metabolic plasticity of #cancer cells.
https://bit.ly/41Al0SQ
Aldolase A: the broker of glycolysis - Nature Metabolism
bit.ly
March 20, 2025 at 5:57 PM
NEWS&VIEWS | LM Nascentes Melo, F Cansiz & A Tasdogan (DKTK, DE)
#AldolaseA inhibition in cancer cells turns #glycolysis into an ATP-consuming process. Imbalanced glycolysis could overcome the intrinsic metabolic plasticity of #cancer cells.
https://bit.ly/41Al0SQ
#AldolaseA inhibition in cancer cells turns #glycolysis into an ATP-consuming process. Imbalanced glycolysis could overcome the intrinsic metabolic plasticity of #cancer cells.
https://bit.ly/41Al0SQ
👍🏻5. Rhein-Main #Cancer Retreat erfolgreich beendet: Die Organisatoren – LOEWE-Frankfurt Cancer Institute @loewe-fci.bsky.social, Deutsches Konsortium für Translationale #Krebsforschung DKTK + Mildred-Scheel-Nachwuchszentrum MSNZ – blicken positiv ins nächste Jahr! #LOEWE #Grundlagenforschung #Hessen
November 19, 2024 at 10:16 AM
👍🏻5. Rhein-Main #Cancer Retreat erfolgreich beendet: Die Organisatoren – LOEWE-Frankfurt Cancer Institute @loewe-fci.bsky.social, Deutsches Konsortium für Translationale #Krebsforschung DKTK + Mildred-Scheel-Nachwuchszentrum MSNZ – blicken positiv ins nächste Jahr! #LOEWE #Grundlagenforschung #Hessen
Would you like to do some unique experiments in cancer genomics and mutagenesis, in beautiful Munich? Well then apply for this PhD position: jobs.dkfz.de/en/jobs/1679...
You'll learn a lot and it'll be fun and interesting!
#DKTK @dkfz.bsky.social @lmumuenchen.bsky.social
You'll learn a lot and it'll be fun and interesting!
#DKTK @dkfz.bsky.social @lmumuenchen.bsky.social
PhD Student in Mutational Processes Driving Somatic Evolution
jobs.dkfz.de
August 19, 2025 at 2:54 PM
Would you like to do some unique experiments in cancer genomics and mutagenesis, in beautiful Munich? Well then apply for this PhD position: jobs.dkfz.de/en/jobs/1679...
You'll learn a lot and it'll be fun and interesting!
#DKTK @dkfz.bsky.social @lmumuenchen.bsky.social
You'll learn a lot and it'll be fun and interesting!
#DKTK @dkfz.bsky.social @lmumuenchen.bsky.social
Dieter Saur @saurlab.bsky.social from the DKTK Munich site and Aurelio Teleman, a metabolism expert at the DKFZ, receive the ERC Advanced Grant. Congratulations! 👏 #ERCAdG @erc.europa.eu
t1p.de/2c18x
t1p.de/2c18x
ERC Advanced Grants for Dieter Saur and Aurelio Teleman
The European Research Council (ERC) supports visionary projects in basic research through its “Advanced Grants.” This year, the Council awarded a grant to cancer researcher and physician Dieter Saur f...
t1p.de
June 23, 2026 at 11:14 AM
Dieter Saur @saurlab.bsky.social from the DKTK Munich site and Aurelio Teleman, a metabolism expert at the DKFZ, receive the ERC Advanced Grant. Congratulations! 👏 #ERCAdG @erc.europa.eu
t1p.de/2c18x
t1p.de/2c18x
ぐんしの映画シリアスなのにdktkの洗脳書物が漫画だし真面目にふせんいっぱい貼ってあるの面白くて大好き
May 25, 2026 at 4:30 PM
ぐんしの映画シリアスなのにdktkの洗脳書物が漫画だし真面目にふせんいっぱい貼ってあるの面白くて大好き
Zwei Wissenschaftlerinnen für Forschung zu bösartigen Hirntumoren ausgezeichnet: Celia Dobersalske vom DKTK-Standort am Westdeutschen Tumorzentrum Essen erhält den @helmholtz.de Doktorandenpreis im Bereich Gesundheit, Pauline Holfelder vom DKFZ den MTZ-Helmholtz Health Award 2025. 👏
t1p.de/v7blr
t1p.de/v7blr
July 14, 2025 at 10:55 AM
Zwei Wissenschaftlerinnen für Forschung zu bösartigen Hirntumoren ausgezeichnet: Celia Dobersalske vom DKTK-Standort am Westdeutschen Tumorzentrum Essen erhält den @helmholtz.de Doktorandenpreis im Bereich Gesundheit, Pauline Holfelder vom DKFZ den MTZ-Helmholtz Health Award 2025. 👏
t1p.de/v7blr
t1p.de/v7blr
𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲 𝗗𝗞𝗙𝗭/𝗡𝗖𝗧/𝗗𝗞𝗧𝗞 𝗛𝗔𝗥𝗣𝗢𝗢𝗡 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 2025 𝗶𝘀 𝗻𝗼𝘄 𝗼𝗽𝗲𝗻! 👍
Hope to see many of you on Nov 27 + 28 at the HCC in Heidelberg...!
Please register here: indico.dkfz.de/event/1230/
Hope to see many of you on Nov 27 + 28 at the HCC in Heidelberg...!
Please register here: indico.dkfz.de/event/1230/
August 7, 2025 at 11:53 AM
𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲 𝗗𝗞𝗙𝗭/𝗡𝗖𝗧/𝗗𝗞𝗧𝗞 𝗛𝗔𝗥𝗣𝗢𝗢𝗡 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 2025 𝗶𝘀 𝗻𝗼𝘄 𝗼𝗽𝗲𝗻! 👍
Hope to see many of you on Nov 27 + 28 at the HCC in Heidelberg...!
Please register here: indico.dkfz.de/event/1230/
Hope to see many of you on Nov 27 + 28 at the HCC in Heidelberg...!
Please register here: indico.dkfz.de/event/1230/
It's been a pleasure to contribute to this interesting documentary by showing how we work to incorporate (phospho-)proteomic information into clinical decision-making in molecular tumor boards as part of the DKFZ/NCT/DKTK MASTER precision oncology program.
Die 3sat-Sendung „Wissen hoch 2 – Die Protein-Revolution“ zeigt, wie die Analyse von Proteinen neue, individuelle Therapien für Krebserkrankungen ermöglicht. Mit dabei: Expert:innen aus dem NCT Heidelberg.
📺 23. Januar, 20:15 Uhr auf 3sat oder in der Mediathek
www.nct-heidelberg.de/das-nct/news...
📺 23. Januar, 20:15 Uhr auf 3sat oder in der Mediathek
www.nct-heidelberg.de/das-nct/news...
January 22, 2025 at 12:22 PM
It's been a pleasure to contribute to this interesting documentary by showing how we work to incorporate (phospho-)proteomic information into clinical decision-making in molecular tumor boards as part of the DKFZ/NCT/DKTK MASTER precision oncology program.
In Heidelberg gibt es das Master Programm für seltene Krebserkrankungen, keine Medikamentenstudie, sondern vertiefte Diagnostik mit z.B. Biopsien für ind. Heilvorschläge, muss dann auch mit KK verhandelt werden, aber bei so fachspezifischen Einrichtungen bessere Chancen: nct.dkfz.de/en/research/...
MASTER: Study on rare types of cancer
In the DKFZ/NCT/DKTK MASTER programme, patients with rare tumours can undergo genetic testing: The aim is to recommend a treatment.
nct.dkfz.de
April 10, 2026 at 6:41 AM
In Heidelberg gibt es das Master Programm für seltene Krebserkrankungen, keine Medikamentenstudie, sondern vertiefte Diagnostik mit z.B. Biopsien für ind. Heilvorschläge, muss dann auch mit KK verhandelt werden, aber bei so fachspezifischen Einrichtungen bessere Chancen: nct.dkfz.de/en/research/...
Great scientific retreat of DKTK Freiburg @dkfz.bsky.social Exciting Science, nice location (Caritas Akademie)
July 8, 2025 at 12:09 PM
Great scientific retreat of DKTK Freiburg @dkfz.bsky.social Exciting Science, nice location (Caritas Akademie)
Join DKFZ/NCT/DKTK HARPOON to explore pioneering precision oncology talks — from AI-powered multiomics data analysis to forward and reverse translation
📅 November 5 - 6
🔗 indico.dkfz.de/e/harpoon2026
@vhio.bsky.social @nct-heidelberg.bsky.social @ki.se @crukcamcentre.bsky.social @nkinl.bsky.social
📅 November 5 - 6
🔗 indico.dkfz.de/e/harpoon2026
@vhio.bsky.social @nct-heidelberg.bsky.social @ki.se @crukcamcentre.bsky.social @nkinl.bsky.social
July 6, 2026 at 10:32 AM
Join DKFZ/NCT/DKTK HARPOON to explore pioneering precision oncology talks — from AI-powered multiomics data analysis to forward and reverse translation
📅 November 5 - 6
🔗 indico.dkfz.de/e/harpoon2026
@vhio.bsky.social @nct-heidelberg.bsky.social @ki.se @crukcamcentre.bsky.social @nkinl.bsky.social
📅 November 5 - 6
🔗 indico.dkfz.de/e/harpoon2026
@vhio.bsky.social @nct-heidelberg.bsky.social @ki.se @crukcamcentre.bsky.social @nkinl.bsky.social
1/2 Super excited to see this finally out @naturecomms.bsky.social ! We developed an off-the-shelf T cell receptor T cell therapy for patients with glioblastoma from a peptide vaccinated patient. Looking very much forward to its translation within DKTK supported by HI-TRON!
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen - Nature Communications
Vaccination in glioblastomas does lead to the emergence of tumour-antigen-specific T cells but T cell dysfunction, poor tumour infiltration and persistence hinder efficient tumour killing. Here author...
www.nature.com
February 2, 2025 at 9:08 PM
1/2 Super excited to see this finally out @naturecomms.bsky.social ! We developed an off-the-shelf T cell receptor T cell therapy for patients with glioblastoma from a peptide vaccinated patient. Looking very much forward to its translation within DKTK supported by HI-TRON!